Associations of blood biomarkers with cardiovascular disease and related cardiometabolic outcomes and risk prediction in the clinical setting
University of Glasgow
Professor Naveed Sattar
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
In UK Biobank planned blood tests are important in helping detect early signs of groups of related diseases in the heart, blood vessels, brain, as well as early signs of diabetes. We will investigate to what extent these blood tests tell us about how likely someone is to develop these conditions, how these conditions develop, and whether we can intervene. For instance, adding information from these tests might improve our ability to predict the risk of a person having a heart attack. By harnessing the power of genes, we will test whether some of these new markers cause disease. This project will aim to assess avenues to improve health care throughout the population by investigating the improvement of CVD risk scores. More sensitive CVD and related risk scores may lead to better targeting of treatment and a reduction in the burden of CVD in the population. Biomarker measurement in UK biobank has been commenced, and the first tranche of biomarkers to be measured are now known. We will assess whether these markers are associated with, and predict, risk of cardiovascular and metabolic-related conditions. Biomarkers of interest include:
Lipids and lipoproteins (different measures of blood cholesterol), markers of inflammation, markers, of liver function, markers of renal function, sex hormones, markers of glucose control, and markers of bone health. Each of these has plausible biological mechanisms linking them to risk of cardiovascular and metabolic diseases. The full cohort with available data will be explored to maximise generalisability to the whole adult population.